Masimo Corporation Intrinsic Value Calculator – MASIMO CORPORATION Reports Third Quarter Earnings for FY2023

November 21, 2023

🌥️Earnings Overview

MASIMO CORPORATION ($NASDAQ:MASI) has released their results for the third quarter of FY2023, which concluded on September 30 2023. Total revenue during this period was USD 478.9 million, a 12.8% decrease from the same quarter in the previous year. The company also reported a 72.0% decrease in net income for the quarter, compared to the same period in the preceding year, amounting to USD 10.6 million.

Price History

The stock opened at $81.6 and closed at $80.6, down by 1.2% from its last closing price of 81.6. The market responded to the earnings report with mixed reactions, as some analysts found the results to be satisfactory while others expressed disappointment.

However, the company’s expenses grew faster than its revenues, leading to a decrease in its gross margin and drop in its per-share earnings.

In addition, the company noted that its research and development costs were higher than expected, which negatively impacted its bottom line. Furthermore, MASIMO CORPORATION’s shares were also affected by a general market decline in the third quarter of FY2023. Despite the mixed reactions to the earnings report, MASIMO CORPORATION’s long-term prospects look promising. The company continues to invest in innovation and has made numerous strategic acquisitions in recent years. With a strong balance sheet and a commitment to growth, MASIMO CORPORATION is well-positioned to benefit from an improving economy. Live Quote…

About the Company

  • Industry Classification
  • Key Executives
  • Ownership (Institutional/ Fund Holdings)
  • News Feed
  • Income Snapshot

    Below shows the total revenue, net income and net margin for Masimo Corporation. More…

    Total Revenues Net Income Net Margin
    2.12k 88.5 4.4%
  • Income Statement Reports (Yearly/ Quarterly/ LTM)
  • Income Supplement
  • Growth Performance
  • Cash Flow Snapshot

    Below shows the cash from operations, investing and financing for Masimo Corporation. More…

    Operations Investing Financing
    10.4 -78.7 -25.5
  • Cash Flow Statement (Yearly/ Quarterly/ LTM)
  • Cash Flow Supplement
  • Balance Sheet Snapshot

    Below shows the total assets, liabilities and book value per share for Masimo Corporation. More…

    Total Assets Total Liabilities Book Value Per Share
    3k 1.72k 24.14
  • Balance Sheet (Yearly/ Quarterly)
  • Balance Sheet Supplement
  • Key Ratios Snapshot

    Some of the financial key ratios for Masimo Corporation are shown below. More…

    3Y Rev Growth 3Y Operating Profit Growth Operating Margin
    24.5% -11.8% 8.0%
    FCF Margin ROE ROA
    -2.8% 8.2% 3.5%
  • Income Statement Ratios
  • Balance Sheet Ratios
  • Cash Flow Ratios
  • Valuation Ratios
  • Other Ratios
  • Other Supplementary Items
  • Analysis – Masimo Corporation Intrinsic Value Calculator

    At GoodWhale, we have conducted an analysis of MASIMO CORPORATION‘s financials and have concluded that the fair value of MASIMO CORPORATION share is around $286.6. This fair value was calculated by our proprietary Valuation Line. Currently, MASIMO CORPORATION stock is traded at $80.6, which is undervalued by 71.9%. This represents an opportunity for investors to capitalize on the discounted price of MASIMO CORPORATION stock. More…

  • Star Chart Analysis
  • Valuation Analysis

  • Peers

    In the medical device industry, there is intense competition between Masimo Corp and its rivals Elekta AB, Essilorluxottica, and Compumedics Ltd. While all four companies offer innovative products and services, each has its own unique strengths and weaknesses. As a result, the competition between them is fierce, and it is often difficult for one company to gain a significant advantage over the others.

    – Elekta AB ($OTCPK:EKTAY)

    Despite a challenging year for the company, Elekta’s market cap has grown to 2.09B as of 2022. This is due in part to the company’s strong return on equity, which stands at 11.86%. Elekta is a leading provider of radiation therapy solutions for the treatment of cancer. The company’s products are used in over 6,000 hospitals and clinics around the world, and its solutions are backed by a team of over 3,000 employees.

    – Essilorluxottica ($LTS:0OMK)

    EssilorLuxottica is a French-Italian multinational corporation that designs, manufactures, and markets ophthalmic lenses, instruments, and equipment. The company has a presence in over 130 countries and employs more than 140,000 people. The company was formed in 2018 through the merger of Essilor International and Luxottica.

    – Compumedics Ltd ($ASX:CMP)

    Computedics Ltd is a technology company that provides computing and analytics solutions. The company has a market cap of 42.52M as of 2022 and a Return on Equity of 1.53%. Computedics Ltd provides computing and analytics solutions to businesses and organizations worldwide. The company offers a range of services, including data storage, cloud computing, data analysis, and security. Computedics Ltd is headquartered in Sydney, Australia.


    Investors in Masimo Corporation should be wary of the company’s third quarter earnings results for FY2023, which showed a decrease in both total revenue and net income compared to the same period in the previous year. Total revenue declined 12.8% to USD 478.9 million and net income dropped 72.0% to USD 10.6 million. However, investors should monitor the company’s performance over time to better understand how it may be impacted in the long-term. Additionally, investors should consider looking at factors such as Masimo’s market position, competitive landscape, and cost structure when evaluating future investment decisions.

    Recent Posts

    Leave a Comment